The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...

A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

Urological surgeons in Nigeria are raising alarms about the increasing number of bladder and testicular cancer cases, a ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

A dad-of-two took his own life after fearing he would become a burden to his family following a bladder cancer diagnosis, an ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

Pfizer (PFE) stock is in focus as the firm with Astellas (ALPMF) post a Phase 3 trial win for Padcev cancer drug when used ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...